⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MESO News
Mesoblast Limited American Depositary Shares
High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD
globenewswire.com
MESO
Ryoncil® Net Revenues Increase for the Quarter to US$30M
globenewswire.com
MESO
Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
globenewswire.com
MESO
FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy
globenewswire.com
MESO
Ryoncil® Sales Increase 60% in December Quarter to US$35.1M
globenewswire.com
MESO
Mesoblast Announces Changes to Board of Directors' Leadership Roles
globenewswire.com
MESO
Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line
globenewswire.com
MESO
Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy
prnewswire.com
PROK
MESO
LCTX
Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD
globenewswire.com
MESO
Mesoblast Participation at Piper Sandler Conference
globenewswire.com
MESO